文献速递细菌感染、耐药与抗菌药物医院感染防控

肝移植受者利奈唑胺群体药代动力学与血小板减少风险

Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

本研究回顾性分析中山医院2019年1月至2022年5月接受利奈唑胺治疗的成人肝移植受者,建立暴露-安全性模型并模拟初始给药方案。发现AUCss,24h阈值291.7 mg/L·h与血小板减少风险增加相关,现有基于协变量的初始剂量推荐欠佳,需TDM指导个体化给药。

要点

  • AUCss,24h阈值291.7 mg/L·h与血小板减少风险增加相关。
  • 基于协变量的初始剂量推荐欠佳,需TDM优化肝移植受者疗效。
  • 在线AUC计算器可供临床及时调整剂量。

核心结论

  • AUCss,24h阈值291.7 mg/L·h与肝移植受者利奈唑胺相关血小板减少风险增加相关。
  • 基于协变量的初始剂量推荐欠佳,AUC指导给药和TDM对优化治疗结局重要。

研究设计与样本

  • 回顾性分析中山医院2019年1月至2022年5月接受利奈唑胺治疗的成人肝移植受者。
  • 建立群体暴露-安全性模型,并通过蒙特卡洛模拟优化初始给药策略。

主要发现

  • 暴露-安全性分析显示AUCss,24h阈值291.7 mg/L·h与血小板减少风险增加相关。
  • 蒙特卡洛模拟显示当前基于协变量的初始剂量推荐欠佳。

关键数值与推荐

  • AUCss,24h阈值291.7 mg/L·h与血小板减少风险增加相关。

临床怎么用

  • 建议进行AUC指导的剂量调整和治疗药物监测以优化肝移植受者治疗结局。
  • 可使用本研究开发的在线AUC计算器实施及时剂量调整。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Linezolid is a commonly prescribed antibiotic for multidrug-resistant enterococcal infections in liver transplant recipients (LTRs). However, changes in pharmacokinetics due to fluctuations in liver and renal functions, combined with the increased risk of thrombocytopenia, complicate its clinical use. This study aimed to characterize the exposure-thrombocytopenia risk relationship of linezolid in LTRs, and to identify safe dosing thresholds to promote rational drug use. METHODS: A retrospective analysis was conducted on adult LTRs treated with linezolid at Zhongshan Hospital between January 2019 and May 2022. A population exposure-safety model was developed and used to establish a thrombocytopenia risk threshold and optimize initial dosing strategies through Monte Carlo simulations. An area under the concentration-time curve (AUC) calculator was developed to facilitate individualized dose adjustments. RESULTS: Exposure-safety analysis revealed that an AUCss,24h threshold of 291.7 mg/L·h was associated with an increased risk of thrombocytopenia. Monte Carlo simulations showed that current covariate-based initial dosing recommendations were suboptimal, highlighting the necessity of therapeutic drug monitoring (TDM) to improve outcomes in LTRs. The online AUC calculator developed in this study offers a practical tool for clinicians to implement timely dose adjustments (https://optimaldose.shinyapps.io/LinezolidAUC/). CONCLUSIONS: This study provides the first comprehensive analysis of linezolid exposure and its relationship to thrombocytopenia risk in LTRs. The findings underscore the importance of AUC-guided dosing and TDM in optimizing treatment outcomes.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Shi X, Yang W, Zhao F, et al. Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients. J Antimicrob Chemother. 2025. PMID: 40358659. doi:10.1093/jac/dkaf147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。